For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Cancer drug announcement: "We're desperately hoping breast cancer patients can have some certainty soon"
+Undoctored
Cancer drug announcement: "We're desperately hoping breast cancer patients can have some certainty soon"
Monday 24 June 2024, 04:41 PM

Responding to the Government’s announcement on cancer drugs this afternoon, Ah-Leen Rayner, chief executive of Breast Cancer Foundation NZ, says:
“This is fantastic news for Kiwis with cancer and we’re excited Minister Reti mentioned breast cancer will be included. We don’t know what this means yet but we’re desperately hoping we, and these patients, can have some certainty soon.
“There are two breast cancer drugs that would make a massive difference and have the same or higher clinical benefit as the ones the Government had campaigned on – we will keep pushing so that women can have these treatments that will give them longer or better lives.”